Brief: Ocean Biomedical Says First Patients Dosed in Phase 1b Study of Novel Immunotherapy
26/10/2023 10:37
Oct 26 (Reuters) - Ocean Biomedical Inc OCEA.O :
* OCEAN BIOMEDICAL (NASDAQ: OCEA) ANNOUNCES FIRST PATIENTS
DOSED
BY JOINT VENTURE PARTNER VIRION THERAPEUTICS IN PHASE 1B STUDY
OF NOVEL IMMUNOTHERAPY FOR CHRONIC HEPATITIS B VIRUS INFECTION
* OCEAN BIOMEDICAL INC-INITIAL CLINICAL DATA FROM THIS STUDY
ARE
EXPECTED IN EARLY 2024
Source text for Eikon: ID:nGNX4Yp2lw
Further company coverage: OCEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocean Biomedical
See all newsTrump's shipbuilding plan could upend ocean cargo industry, companies warn
Brief: Ocean Biomedical Announces Breakthrough Findings In EGFR-Mutant Lung Cancer
Brief: Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q
Brief: Ocean Biomedical receives Nasdaq staff determination letter
Brief: Ocean Biomedical- Ratified Fully Countersigned Copy Of Revised Agreement With Virion Therapeutics Received On Sept 26